Cargando…

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific biochemical markers are not available. Here, we investigated the potential of cerebrospinal fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuronal damage in vas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llorens, Franc, Hermann, Peter, Villar-Piqué, Anna, Diaz-Lucena, Daniela, Nägga, Katarina, Hansson, Oskar, Santana, Isabel, Schmitz, Matthias, Schmidt, Christian, Varges, Daniela, Goebel, Stefan, Dumurgier, Julien, Zetterberg, Henrik, Blennow, Kaj, Paquet, Claire, Baldeiras, Inês, Ferrer, Isidro, Zerr, Inga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992814/ https://www.ncbi.nlm.nih.gov/pubmed/32001681 http://dx.doi.org/10.1038/s41467-020-14373-2

Ejemplares similares

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers
por: Hermann, Peter, et al.
Publicado: (2022)

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease
por: Zerr, Inga, et al.
Publicado: (2021)

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
por: Canaslan, Sezgi, et al.
Publicado: (2021)

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie
por: Schmitz, Matthias, et al.
Publicado: (2016)

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
por: van Westen, Danielle, et al.
Publicado: (2016)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis
por: Zerr, Inga, et al.
Publicado: (2020)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
por: Schmitz, Matthias, et al.
Publicado: (2022)

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later
por: Nägga, Katarina, et al.
Publicado: (2018)

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients
por: Schmitz, Matthias, et al.
Publicado: (2016)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
por: Llorens, Franc, et al.
Publicado: (2017)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
por: Podlesniy, Petar, et al.
Publicado: (2020)

Progress in CSF biomarker discovery in sCJD
por: Llorens, Franc, et al.
Publicado: (2016)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App(NL−F/NL−F) knock-in mouse model of Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mfdhftuobbi8bvivq3s675mnpv